A new study found patients with T1D and T2D had a greater risk for stenotic lesions, whereas risk for valvular regurgitation was lower in those with T2D.
ADA 2022: Patients with T2D who received a treatment intervention powered by artificial intelligence achieved a remission rate of more than 80%.
ADA 2022: "Breakthrough" findings may help to address the unmet need for additional treatment options for young patients with type 2 diabetes.
ADA 2022: Younger age, insulin use, higher HbA1c, and higher diabetes distress were found to be associated with CGM uptake in prospective study.
ADA 2022: In a new literature review, 43% of studies included identified diabetes as a potent risk for developing post-acute sequelae of COVID-19.
ADA 2022: Tirzepatide led overall to weight loss of up to 22.5% of baseline body weight with persons taking the 15 mg dose losing an average of 52 pounds.
Compare, contrast, price shop, prescribe. DiabetesWise Pro developer Korey Hood, PhD, highlights the tool all primary care clinicians should try.
Mikhail Kosiborod, MD, a cardiologist and Neil Skolnik, MD, a primary care physician, agree that whoever is seeing the patient should prescribe the drug that is needed.
Lowering thresholds for BMI value and age of first diabetes screening among large US minority populations could greatly increase rates of diagnosis and improve care.
HbA1c levels over time were found higher at initiation of second-line treatment in veterans aged 55 years and younger, a trend unsettling to a new study's lead author.